Survival of patients with myelofibrosis who undergo splenectomy is adversely affected by older age, the need for transfusion, and leukocyte and circulating blast cell counts, according to a new analysis.
A new study including two separate cohorts found that male gender is a significant risk factor for mortality in patients with essential thrombocythemia. Gender may play a bigger role than thrombosis history in determining risk.
In this review, we demonstrate the evolving landscape of clinical investigation as researchers and clinicians attempt to address the important therapeutic needs of patients with myeloproliferative neoplasms.
A 60-year-old man with a history of coronary artery disease and JAK2 V617F–positive polycythemia vera presented to our bone marrow transplantation clinic with progressive fatigue, splenomegaly, and cytopenias.
Myeloproliferative neoplasms are a group of clonal myeloid cell–derived disorders characterized by myeloproliferation without dysplasia, bone marrow hypercellularity, and predisposition to thrombosis, hemorrhage, and bone marrow fibrosis.